Squarepoint Ops LLC Makes New $214,000 Investment in Pediatrix Medical Group, Inc. (NYSE:MD)

Squarepoint Ops LLC purchased a new stake in Pediatrix Medical Group, Inc. (NYSE:MD) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 28,286 shares of the company’s stock, valued at approximately $214,000.

A number of other hedge funds also recently made changes to their positions in MD. Aristeia Capital L.L.C. acquired a new stake in Pediatrix Medical Group in the second quarter valued at approximately $687,000. Vanguard Group Inc. lifted its stake in shares of Pediatrix Medical Group by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock valued at $105,892,000 after acquiring an additional 164,333 shares during the last quarter. Boston Partners boosted its holdings in shares of Pediatrix Medical Group by 34.0% during the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after acquiring an additional 453,254 shares in the last quarter. Rubric Capital Management LP grew its position in Pediatrix Medical Group by 797.0% during the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after acquiring an additional 7,241,400 shares during the last quarter. Finally, ClariVest Asset Management LLC bought a new stake in Pediatrix Medical Group during the 2nd quarter worth $1,721,000. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently commented on MD. StockNews.com raised Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research note on Wednesday, August 7th. UBS Group lifted their target price on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Jefferies Financial Group upgraded shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating and upped their price target for the company from $8.00 to $14.00 in a research report on Thursday, September 26th. Finally, Truist Financial lifted their price target on shares of Pediatrix Medical Group from $10.00 to $13.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $10.90.

Insiders Place Their Bets

In other Pediatrix Medical Group news, CFO C Marc Richards sold 32,562 shares of the stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $10.08, for a total transaction of $328,224.96. Following the transaction, the chief financial officer now directly owns 192,785 shares in the company, valued at approximately $1,943,272.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Laura A. Linynsky sold 7,000 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the sale, the director now directly owns 30,805 shares of the company’s stock, valued at $343,783.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO C Marc Richards sold 32,562 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $10.08, for a total value of $328,224.96. Following the transaction, the chief financial officer now directly owns 192,785 shares in the company, valued at approximately $1,943,272.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 68,100 shares of company stock worth $701,889. 2.00% of the stock is owned by corporate insiders.

Pediatrix Medical Group Trading Up 0.9 %

NYSE:MD opened at $12.11 on Friday. Pediatrix Medical Group, Inc. has a 52 week low of $6.62 and a 52 week high of $13.01. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.38 and a current ratio of 1.38. The firm’s fifty day moving average is $10.82 and its 200-day moving average is $9.06. The firm has a market cap of $1.02 billion, a P/E ratio of -14.25, a P/E/G ratio of 1.84 and a beta of 1.56.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.03. The firm had revenue of $504.30 million during the quarter, compared to the consensus estimate of $505.49 million. Pediatrix Medical Group had a positive return on equity of 10.59% and a negative net margin of 12.58%. The business’s revenue was up .7% compared to the same quarter last year. During the same period last year, the business posted $0.37 EPS. Equities analysts expect that Pediatrix Medical Group, Inc. will post 1.19 earnings per share for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.